Cargando…
Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells
Human Cytomegalovirus (CMV) reactivation remains a major source of morbidity in patients after solid organ and hematopoietic stem cell transplantation (HSCT). Adoptive T cell therapy (ACT) with CMV-specific T cells is a promising therapeutic approach for HSCT recipients, but might be counteracted by...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831000/ https://www.ncbi.nlm.nih.gov/pubmed/29489900 http://dx.doi.org/10.1371/journal.pone.0193554 |
_version_ | 1783303106461696000 |
---|---|
author | Schlott, Fabian Steubl, Dominik Ameres, Stefanie Moosmann, Andreas Dreher, Stefan Heemann, Uwe Hösel, Volker Busch, Dirk H. Neuenhahn, Michael |
author_facet | Schlott, Fabian Steubl, Dominik Ameres, Stefanie Moosmann, Andreas Dreher, Stefan Heemann, Uwe Hösel, Volker Busch, Dirk H. Neuenhahn, Michael |
author_sort | Schlott, Fabian |
collection | PubMed |
description | Human Cytomegalovirus (CMV) reactivation remains a major source of morbidity in patients after solid organ and hematopoietic stem cell transplantation (HSCT). Adoptive T cell therapy (ACT) with CMV-specific T cells is a promising therapeutic approach for HSCT recipients, but might be counteracted by CMV’s immune evasion strategies. HLA-C*07:02 is less susceptible to viral immune evasion suggesting HLA-C*07:02-restricted viral epitopes as promising targets for ACT. For a better understanding of HLA-C*07:02-restricted CMV-specific T cells we used recently generated reversible HLA-C*07:02/IE-1 multimers (Streptamers) recognizing a CMV-derived Immediate-Early-1 (IE-1) epitope and analyzed phenotypic and functional T cell characteristics. Initially, we detected very high frequencies of HLA-C*07:02/IE-1 multimer(+) T cells (median = 11.35%), as well as robust functional responses after stimulation with IE-1 peptide (IFNγ(+); median = 5.02%) in healthy individuals. However, MHC-multimer(+) and IFNγ-secreting T cell frequencies showed a relatively weak correlation (r(2) = 0.77), which could be attributed to an unexpected contribution of CMV-epitope-independent KIR2DL2/3-binding of HLA-C*07:02/IE-1 multimers. Therefore, we developed a MHC-multimer double-staining approach against a cancer epitope-specific HLA-C*07:02 multimer to identify truly HLA-C*07:02/IE-1 epitope-specific T cells. The frequencies of these truly HLA-C*07:02/IE-1 multimer(+) T cells were still high (median = 6.86%) and correlated now strongly (r(2) = 0.96) with IFNγ-secretion. Interestingly, HLA-C*07:02/IE-1-restricted T cells contain substantial numbers with a central memory T cell phenotype, indicating high expansion potential e.g. for ACT. In line with that, we developed a clinical enrichment protocol avoiding epitope-independent KIR-binding to make HLA-C*07:02/IE-1-restricted T cells available for ACT. Initial depletion of KIR-expressing CD8(+) T cells followed by HLA-C*07:02/IE-1 Streptamer positive selection using paramagnetic labeling techniques allowed to enrich successfully HLA-C*07:02/IE-1-restricted T cells. Such specifically enriched populations of functional HLA-C*07:02/IE-1-restricted T cells with significant central memory T cell content could become a potent source for ACT. |
format | Online Article Text |
id | pubmed-5831000 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-58310002018-03-19 Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells Schlott, Fabian Steubl, Dominik Ameres, Stefanie Moosmann, Andreas Dreher, Stefan Heemann, Uwe Hösel, Volker Busch, Dirk H. Neuenhahn, Michael PLoS One Research Article Human Cytomegalovirus (CMV) reactivation remains a major source of morbidity in patients after solid organ and hematopoietic stem cell transplantation (HSCT). Adoptive T cell therapy (ACT) with CMV-specific T cells is a promising therapeutic approach for HSCT recipients, but might be counteracted by CMV’s immune evasion strategies. HLA-C*07:02 is less susceptible to viral immune evasion suggesting HLA-C*07:02-restricted viral epitopes as promising targets for ACT. For a better understanding of HLA-C*07:02-restricted CMV-specific T cells we used recently generated reversible HLA-C*07:02/IE-1 multimers (Streptamers) recognizing a CMV-derived Immediate-Early-1 (IE-1) epitope and analyzed phenotypic and functional T cell characteristics. Initially, we detected very high frequencies of HLA-C*07:02/IE-1 multimer(+) T cells (median = 11.35%), as well as robust functional responses after stimulation with IE-1 peptide (IFNγ(+); median = 5.02%) in healthy individuals. However, MHC-multimer(+) and IFNγ-secreting T cell frequencies showed a relatively weak correlation (r(2) = 0.77), which could be attributed to an unexpected contribution of CMV-epitope-independent KIR2DL2/3-binding of HLA-C*07:02/IE-1 multimers. Therefore, we developed a MHC-multimer double-staining approach against a cancer epitope-specific HLA-C*07:02 multimer to identify truly HLA-C*07:02/IE-1 epitope-specific T cells. The frequencies of these truly HLA-C*07:02/IE-1 multimer(+) T cells were still high (median = 6.86%) and correlated now strongly (r(2) = 0.96) with IFNγ-secretion. Interestingly, HLA-C*07:02/IE-1-restricted T cells contain substantial numbers with a central memory T cell phenotype, indicating high expansion potential e.g. for ACT. In line with that, we developed a clinical enrichment protocol avoiding epitope-independent KIR-binding to make HLA-C*07:02/IE-1-restricted T cells available for ACT. Initial depletion of KIR-expressing CD8(+) T cells followed by HLA-C*07:02/IE-1 Streptamer positive selection using paramagnetic labeling techniques allowed to enrich successfully HLA-C*07:02/IE-1-restricted T cells. Such specifically enriched populations of functional HLA-C*07:02/IE-1-restricted T cells with significant central memory T cell content could become a potent source for ACT. Public Library of Science 2018-02-28 /pmc/articles/PMC5831000/ /pubmed/29489900 http://dx.doi.org/10.1371/journal.pone.0193554 Text en © 2018 Schlott et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Schlott, Fabian Steubl, Dominik Ameres, Stefanie Moosmann, Andreas Dreher, Stefan Heemann, Uwe Hösel, Volker Busch, Dirk H. Neuenhahn, Michael Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells |
title | Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells |
title_full | Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells |
title_fullStr | Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells |
title_full_unstemmed | Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells |
title_short | Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8(+) T cells |
title_sort | characterization and clinical enrichment of hla-c*07:02-restricted cytomegalovirus-specific cd8(+) t cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831000/ https://www.ncbi.nlm.nih.gov/pubmed/29489900 http://dx.doi.org/10.1371/journal.pone.0193554 |
work_keys_str_mv | AT schlottfabian characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells AT steubldominik characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells AT ameresstefanie characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells AT moosmannandreas characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells AT dreherstefan characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells AT heemannuwe characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells AT hoselvolker characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells AT buschdirkh characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells AT neuenhahnmichael characterizationandclinicalenrichmentofhlac0702restrictedcytomegalovirusspecificcd8tcells |